Recursion Pharmaceuticals Stock Investor Sentiment
| RXRX Stock | USD 4.37 0.04 0.92% |
Slightly above 56% of all Recursion Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Recursion Pharmaceuticals suggests that some traders are interested. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 56
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Recursion Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Recursion Pharmaceuticals.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Recursion Historical Sentiment
Although Recursion Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Recursion, such as negative comments on social media and news outlets, may cause fear in the market and push Recursion Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Recursion.
Recursion | Build AI portfolio with Recursion Stock |
Recursion Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Recursion Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Recursion Pharmaceuticals Historical Investor Sentiment
Investor biases related to Recursion Pharmaceuticals' public news can be used to forecast risks associated with an investment in Recursion. The trend in average sentiment can be used to explain how an investor holding Recursion can time the market purely based on public headlines and social activities around Recursion Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Recursion Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Recursion Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Recursion Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Recursion Pharmaceuticals.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Recursion Pharmaceuticals' Stock prices. Below is the latest headlines and news related to Recursion Pharmaceuticals Stock. The global stock market is bullish. About 67% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Recursion Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Recursion Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Recursion-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Recursion Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Recursion Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Recursion Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Recursion Pharmaceuticals alpha.
Recursion Largest EPS Surprises
Earnings surprises can significantly impact Recursion Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2025-08-05 | 2025-06-30 | -0.35 | -0.41 | -0.06 | 17 | ||
2022-03-23 | 2021-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2021-08-13 | 2021-06-30 | -0.23 | -0.31 | -0.08 | 34 | ||
2025-02-25 | 2024-12-31 | -0.4168 | -0.53 | -0.1132 | 27 | ||
2022-05-10 | 2022-03-31 | 0.1 | -0.33 | -0.43 | 430 |
There is far too much social signal, news, headlines, and media speculation about Recursion Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Recursion Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Recursion-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Recursion Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Recursion Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Recursion Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Recursion Pharmaceuticals alpha.
Recursion Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals subject to Rule 16b-3 | 09/10/2025 |
2 | Insider Trading | 09/18/2025 |
3 | Recursion Pharmaceuticals Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 10/02/2025 |
4 | Is Recursion Pharmaceuticals a Millionaire Maker | 10/16/2025 |
5 | Disposition of 100000 shares by Christopher Gibson of Recursion Pharmaceuticals at 5.7 subject to Rule 16b-3 | 10/23/2025 |
6 | Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th | 10/28/2025 |
7 | Recursion Announces CEO Transition Plan to Drive Next Phase of Growth | 11/05/2025 |
8 | RXRX Q3 Loss Narrower Than Expected, Revenues Decline YY | 11/06/2025 |
9 | Recursion Pharmaceuticals, Inc. Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates | 11/07/2025 |
10 | Forget Recursion Pharmaceuticals This Could Be an Even Better Artificial Intelligence Stock | 11/12/2025 |
11 | Disposition of 40390 shares by Christopher Gibson of Recursion Pharmaceuticals at 4.14 subject to Rule 16b-3 | 11/17/2025 |
12 | Disposition of 40000 shares by Christopher Gibson of Recursion Pharmaceuticals at 4.16 subject to Rule 16b-3 | 11/19/2025 |
13 | Is Recursion Pharmaceuticals Inc. One of the Best Mid Cap Stocks to Buy According to Hedge Funds | 11/21/2025 |
14 | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence Stock | 11/24/2025 |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.